The Serum Institute of India (SII) is a global leader in making vaccines. Its CEO Adar Poonawalla spoke to NDTV on a range of issues, key among them the vaccine for malaria and other mosquito ...

Amid a growing national debate on work-life balance sparked by recent comments from industry leaders, Adar Poonawalla, chief executive officer of Serum Institute of India, has emphasised the ...

Quality of work over quantity always': Adar Poonawalla hits out at L&T chairman’s 90-hour workweek call. (Reuters) The debate over Larsen & Toubro (L&T) Chairman SN Subrahmanyan’s ...

Working hours for people vary based on individual roles, but sustained overwork shouldn’t be the norm, believes Adar Poonawalla, chief executive of Serum Institute of India. Expressing skepticism ...

The panel featured distinguished participants: Pedro Sánchez, Prime Minister of Spain; Vasant Narasimhan, CEO of Novartis International; Sania Nishtar, CEO of GAVI; Adar Poonawalla, CEO of the ...

Adar Poonawalla, CEO of Serum Institute of India feels that longer workweeks won't boost productivity. He feels that productivity dips after 8 hours, Business Today reported. These comments come ...

The turnaround at Poonawalla Fincorp is already underway, according to Adar Poonawalla, Chairman of the company. Speaking about the strategic overhaul following its acquisition of Magma Fincorp, ...

Adar Poonawalla, CEO of the Serum Institute of India, weighed in on the ongoing debate over work-life balance and productivity, particularly in light of recent discussions around 70-hour and 90 ...

From Serum Institute of India helping combat mosquito-borne diseases to the impact of the US withdrawal of funding from the World Health Organization, Chief Executive Officer Adar Poonawalla shared ...

Business tycoon Adar Poonawalla, who recently acquired a 50 percent stake in Karan Johar`s Dharma Productions hosted a lavish New Year party attended by celebs. In the pictures shared by Adar`s ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about concerns of a slowdown in vaccine approvals, on Serum’s upcoming vaccines including BCG and HPV and on investments outside ...